Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brepocitinib - Priovant Therapeutics

Next Previous
Drug Profile

Brepocitinib - Priovant Therapeutics

Alternative Names: Brepocitinib tosylate - Pfizer; PF 6700841; PF-06700841; PF-06700841-15; PF-841

Latest Information Update: 11 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Priovant Therapeutics
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Arylsulfonic acids; Bridged-ring heterocyclic compounds; Cyclopropanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Dermatomyositis
  • Phase III Uveitis
  • Phase II Crohn's disease; Hidradenitis suppurativa; Sarcoidosis
  • Discontinued Alopecia; Alopecia areata; Atopic dermatitis; Lupus vulgaris; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo

Most Recent Events

  • 03 Mar 2026 Priovant plans to launch Brepocitinib in US at the end of September 2026
  • 03 Mar 2026 The US FDA accepts and grants priority review for New Drug Application (NDA) for Brepocitinib for Bermatomyositis
  • 03 Mar 2026 US FDA assigns PDUFA action date of 30 September 2026 for Brepocitinib in Dermatomyositis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top